Objective: To attempt to determine the relative value of preclinical cardiac electrophysiology data (in vitro and in vivo) for predicting risk of torsade de pointes (TdP) in clinical use. Methods: Published data on hERG (or I ) activity, cardiac action potential duration (at Kr 90% repolarisation; APD ), and QT prolongation in dogs were compared against QT effects and reports of TdP in humans for 100 drugs.
R elationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of Keywords: Antiarrhythmic agents; Arrhythmia (mechanisms); Ion channels; K-channel; Long QT syndrome; Repolarization; Sudden death; Ventricular arrhythmias
. Introduction
potential duration in vitro, prolongation of QT interval in dogs, and QT prolongation in man were collated and Drug-induced QT interval prolongation and the appeartabulated. It is hoped that these data, presented together for ance of torsade de pointes (TdP) has become recognised as the first time, will assist in the ongoing debate around the a potential risk during treatment with a broad range of preclinical detection of torsadogenic propensity, provide drugs including repolarisation-delaying antiarrhythmics evidence for setting provisional safety margins, and en- [1] , various antihistamines [2, 3] , antipsychotics [4] , anticourage further research. microbial agents [5] , and miscellaneous others [5] [6] [7] [8] [9] [10] . For the vast majority of these agents it has been demonstrated that the slowing of repolarisation is a consequence of 2 . Methods inhibition of the rapidly activating delayed rectifier potassium current (I ) in cardiac tissues, which is conveyed by Kr The approach was as follows: the human ether-a-go-go-related gene-encoded voltage-de-1 pendent potassium channel (hERG K channel; IUPHAR 1 A list of 100 drugs was compiled, covering a range of classification: K 11.1 [11] ). v therapeutic classes. This list included the majority of In 1997, the Committee for Proprietary Medicinal drugs that have been associated with TdP or QT Products (CPMP) published a 'Points to Consider' docuprolongation in man, together with other drugs that have ment that made recommendations for non-clinical and no such association, but which have come under a clinical approaches to assess the risk of QT interval certain degree of scrutiny because of therapeutic class, prolongation and TdP for non-cardiovascular drugs [12] . drug interactions, etc., in addition to drugs designed to Since the appearance of this document, there has been delay cardiac repolarisation (i.e. Class Ia and III antiarmuch debate within the pharmaceutical industry as to the rhythmics). relative merits of various in vitro and in vivo techniques in 2 These drugs were assigned to five categories of tordetecting such activity preclinically [13] [14] [15] . A survey of sadogenic propensity: practice within the industry conducted approximately 2 years after publication of the CPMP document indicated that whereas the industry was taking this issue very Category 1: Repolarisation-prolonging (Class Ia and seriously, there was wide variability in approach [16] .
Class III) antiarrhythmics (which have I block as an Kr One reason for the lack of confidence in the predictive integral pharmacodynamic mechanism, and QT prolongavalue of the preclinical tests is that each drug associated tion as an intended, desirable effect). with TdP in man appears to tell a different story in terms Category 2: Drugs that have been withdrawn or susof its electrophysiological profile. Clearly there is a pended from the market in at least one major regulatory consensus about the importance of interactions with the territory due to an unacceptable risk of TdP for the 1 hERG K channel but even so there is no agreement, condition being treated. either within the pharmaceutical industry or drug regulaCategory 3: Drugs that have a measurable incidence of tory authorities, about what constitutes a safe margin. Risk TdP in humans, or for which numerous case reports exist assessment is further complicated when a drug acts on in the published literature.
1 other cardiac ion channels in addition to the hERG K Category 4: Drugs for which there have been isolated channel, as is often the case.
reports of TdP in humans. We therefore undertook a literature survey of nonCategory 5: Drugs for which there have been no clinical and clinical data on an initial list of 100 drugs, in published reports of TdP in humans. This category also order to assess the predictivity of the various types of data.
contains some drugs (e.g. ketoconazole) which are associThe drugs were first categorised according to their torated with drug interactions leading to TdP, but which have sadogenic propensity, then information on effective free not been associated with cases of TdP when used alone. therapeutic plasma concentration (ETPC ) with inhi-N.B. Erythromycin appears twice in the above list, as unbound bition of hERG /I current, effects on cardiac action there are two formulations with different torsadogenic Kr propensities: intravenous (Category 3) and oral (Category 4). Mibefradil was withdrawn from the market after less than a year due to drug interactions leading to TdP;
Time for primary review 36 days.
however, there was no clear evidence that this drug caused TdP by itself [17] , so it has not been assigned to Category dogs, or other species if dog data were unavailable. 2. Instead, it has been assigned to Category 4, as there is Such data were found to be rarely available outside one report of TdP in the literature [18] . were close to those causing electrophysiological effects in true for Categories 2 ('withdrawn /suspended due to TdP') the preclinical tests ( Fig. 1) . Unfortunately, such data were and 3 ('measurable incidence /numerous reports of TdP').
rarely available outside this category, so no clear pattern There was a mixed picture for drugs assigned to Category can be discerned. Here again, the notable exception was amiodarone, where concentration-effect data are available for most of the the QTc change was observed within the ETPC electrophysiological variables. These more detailed overlay unbound range, whereas the in vitro electrophysiology changes plots confirmed and extended the above findings. For required much higher concentrations (as mentioned above).
('isolated reports of TdP in humans'
dofetilide (an example of a Category 1 drug) the conIn Category 2, a 10-20% increase in QTc in vivo was centration-effect plots for hERG /I , APD and human Kr 90 achieved at lower concentrations than the hERG /I IC QTc were superimposable. In the case of terfenadine Kr 50 for cisapride, sertindole and terfenadine, whereas for (Category 2), the effects on APD and QT were either Obviously, a decision to withdraw / suspend travenous), structural heart disease, prolonged baseline QT from sale does not necessarily relate solely to the incidence interval and genetic variants (polymorphisms and mutaof TdP, as other factors such as the severity of the disease tions) [25] . It has been suggested that these risk factors act target and the availability of alternative drugs are taken by reducing the net repolarising current, thereby limiting into account before such a decision is reached. From the the 'repolarisation reserve' [26] . TdP can also occur as a available evidence it does not appear to be related to result of localised cardiac ischaemia, and such arrhythmias dosing regimen or duration of therapy. are seen, albeit rarely, after myocardial infarction [27] .
One possible explanation is the margin between the concentrations required for clinical efficacy and the con- those drugs that have either been associated with QT relationships, or both. In addition, the action potential data prolongation and TdP in man, or have come under are subject to the complications of species differences, suspicion due to their therapeutic class. It is quite likely frequency-dependence, possible residual effects of anaesthat a 'hERG screening of the pharmacopea' would thetics used and, with some drugs, binding to non-bio-1 unearth some potent hERG K channel blockers that have logical surfaces within the perfusion system, whereas QT never been associated with QT prolongation or TdP, to add data are susceptible to problems caused by inappropriate to one such compound in our dataset: verapamil (see correction for changes in heart rate and (for anaesthetised below). Secondly, the relative torsadogenic propensity in preparations) effects of commonly-used anaesthetics on QT clinical use is difficult to judge within each of our interval [16] . Clearly we should focus on margins rather 1 categories, as this would also have to take into account the than absolute potency at the hERG K channel: although size and nature of the patient population, and the typical all but one (grepafloxacin) of the drugs in Category 2 duration of treatment. In addition, some of the apparent ('withdrawn / suspended from the market due to TdP') were more potent hERG /I blockers than any of the drugs CYP3A4 [2] . However, ketoconazole does prolong the QT Kr in Category 5 ('no reports of TdP'), the important differinterval by itself in guinea-pigs [33] [34] [35] , and so an 1 ences between our 5 categories are to be found in the additive effect in blocking the hERG K channel may margin data (Fig. 2) .
contribute to the proarrhythmic potential of this coFrom our dataset, generally speaking, drugs with little or therapy. There has been only one report of TdP with no margin between ETPC and hERG /I IC are fluoxetine since its launch in the mid-1980s, in an elderly unbound Kr 50 associated with TdP in man, whereas those with a large female patient [36] . The authors hypothesised that this margin are not. Notable exceptions to this are discussed episode could have been due to enhancement of 5-HTbelow. Setting aside these 'outliers', the range of margins induced vasoconstriction, which has been observed to within each of Categories 1-3 were similar (approximately occur in coronary arteries with damaged endothelium. The 0.01-to 30-fold), whereas those in Category 5 were greater incidence of TdP with ciprofloxacin is extremely low (0.3 than 30-fold, with the exception of phenytoin (23-fold) and cases per 10 million prescriptions), this value based on two cibenzoline (24-fold) which fell just short of this margin.
reports as part of a historical cohort study over a 5.5-year Category 4 ('isolated reports of TdP') was an interesting period [37]. These were not accompanied by any ECG 'mixed bag', containing one drug with hERG /I activity recordings, details of the patients, or information on any Kr within its therapeutic plasma concentration range (sparfloxco-therapy, so it remains unproven as to whether the acin), whereas the remainder at least had some therapeutic episodes were due directly to the drug. In terms of margin, as expected. It is possible that some other property explaining these events, ciprofloxacin could cause release (or lack of one) of this antibiotic mitigates against a high of histamine [38] , which in turn could cause coronary incidence of TdP.
vasoconstriction appears to be a line of demarcation between the majority since the mid-1940s, both as a prescription drug and in of drugs associated with TdP and those which are not.
various over-the-counter medicines, yet we could only find However, there are some notable exceptions to this: two apparent cases of TdP in the literature. As there were amiodarone (1400-fold), fluoxetine (106-fold), ciprofloxano details given as to co-therapy, underlying disease, or the cin (183-fold), diphenhydramine (880-fold), and nifedipine arrhythmia itself, these two cases cannot confidently be (35 700-fold), which have each been associated with TdP.
ascribed to an effect of this drug. As with ciprofloxacin, Conversely, the margin for verapamil is less than twofold, these reports were part of a historical cohort study and yet this drug does not prolong QT, let alone induce TdP, were not accompanied by any details of the patients [40] . and ketoconazole also has a small (11-fold) margin but These reports are surprising in view of the absence of TdP apparently is not proarrhythmic. What are the possible with this drug even after overdose [41] . Perhaps the largest explanations for the 'false negatives' and the two 'false anomaly of all is the huge margin for nifedipine. There positives'? Amiodarone is an atypical Class III antiarrhythhave been two reports of TdP in over 20 years of clinical mic, and some commentators have questioned whether it use of this drug. Both of these were in patients with should really be considered to belong to this class [14] , as cardiovascular disease, and both episodes were attributed it also exhibits Class I, II and IV activity, together with to localised myocardial ischaemia caused by coronary vasodilator and anti-ischaemic effects [ [32] . Ketoconazole transfected cell lines (see Fig. 3 for examples) reveals that also has a small margin (11-fold), yet has not been for all drugs there is at most approximately one log order associated with TdP when administered as the sole medicaof magnitude between a 'threshold effect' and the IC . would suffice, whereas in practice the 'safe' margin the sodium and L-type calcium channels) offset the effects appears to be 30-fold (Fig. 2) . There are various possible of inhibition of I on APD and QT interval. variations in the functionality of the hERG K channel a key risk factor, it is conceivable that the plasma (e.g. channel density), or fluctuations in function due to concentration required for arrhythmogenesis with some changes in electrolyte concentrations.
mixed-activity compounds could be quite precise-at a A debate has also begun about whether to use IC certain concentration, the combined ion channel effects 20 values or even IC values for hERG instead of the IC . may interact to produce the conditions for ar- 10 50 The rationale for retaining the use of IC values is rhythmogenesis. In this hypothetical scenario, the risk of 50 obvious, as this is the most accurate measurement that can TdP would be reduced at concentrations above and below be made from a sigmoidal log concentration-effect curve, this critical point. Evidence exists for this hypothesis in the and in the case of hERG assays, as indicated above, the case of quinidine, for example [49] . shape and slope of the curves are very similar across One point to make here is that we should not take nearly all drugs tested. It is therefore better to retain the comfort in a non-antiarrhythmic candidate drug with mixed 1 most accurate and familiar measure of drug potency at the channel activity that is active at the hERG K channel at 1 hERG K channel (i.e. the IC ) and adjust the safety concentrations close to its therapeutic range, but produces 50 margins upwards accordingly, rather than to set a smaller relatively little QT prolongation. Given that the holy grail margin based on an intercept derived from an unreliable of Class III antiarrhythmic research programmes is to part of the sigmoidal log concentration-effect curve, achieve agents with the 'right' balance of ion channel barely above the background noise. However, this stateactivity [50] , the likelihood of a non-antiarrhythmic rement should not be taken to mean that a 10-20% inhibisearch programme achieving this by good fortune is surely tion of I current is of negligible physiological signifiquite low. Put another way, we are more likely to end up Kr cance: from our dataset it is reasonable to conclude that a with a 'terfenadine' than a 'verapamil'. We should ask 10-20% inhibition of I current in a hERG assay would ourselves whether we want potent activity at a range of Kr translate into detectable increases in APD and QT cardiac ion channels in (say) a drug to treat arthritis. 
.6. Mixed ion channel activity
hERG K channel blockers in our list are torsadogenic, drugs with the same potency at the channel may not From our dataset, it would appear that drugs which are necessarily carry the same torsadogenic risk. The nature of 1 relatively selective for the hERG K channel compared to the interaction with the channel may be important; for other cardiac ion channels (especially Class Ia and III example, it has been postulated that there may be multiple antiarrhythmics, with the exception of amiodarone) have binding sites on the channel [51] even for a single drug concentration-effect curves for inhibition of hERG /I , (bepridil) [29] , as well as for different classes of drugs, Kr APD and QT interval (in dog and human) that are including the possibility of intracellular binding sites [52] . 90 virtually superimposable (Figs. 1 and 3) . Those with mixed Also, different drugs bind to the channel in its different ion channel activity (e.g. terfenadine) do not: the constates (closed, open, inactivated) [51, 53] . There are likely centrations required for prolongation of APD and QT to be further developments in this area. Regardless of how 90 1 interval are dissociated from those blocking hERG /I . a particular drug binds to the hERG K channel, the Kr Presumably their effects on other ion channels (primarily prolongation of APD that ensues may not be the defining 90 factor in terms of arrhythmogenesis: the ensuing shape and a pragmatic approach for the pharmaceutical industry stability of the action potential may be critical. Prolongawould be to limit structural / physicochemical similarities to 'triangulation') appears to be associated with known chemical series with the least hERG activity. Structural 1 arrhythmogenic compounds in a rabbit Langendorff-heart requirements for binding to the hERG K channel have preparation, and leads to the appearance of EADs, whereas been characterised, at least for antihistamines [57] [58] [59] and prolongation of APD per se is antiarrhythmic [54] . Other class III antiarrhythmics [60] , and the binding sites on the 90 risk factors for arrhythmogenesis are temporal instability hERG protein have been modelled [61, 62] ; nonetheless, a of the action potential duration within a train, and reversesignificant effort is required to better understand these frequency dependence [54] . Finally, at the multicellular structure-activity relationships. However, series with level there is heterogeneity in sensitivity of cell types hERG activity need not necessarily be rejected: it depends across the ventricular wall to prolongation of APD by any on the severity of the therapeutic target (see below). Data given drug, and the sensitivity range varies between drugs on hERG activity is useful in the early stages of drug [55, 56] .
discovery, but as the research project progresses, not only There are several examples in our dataset of drugs that is it prudent to establish the effects on the cardiac action would be expected to completely inhibit I currents within potential, this is recommended by regulatory authorities Kr their therapeutic range (e.g. quinidine, ibutilide terodiline, prior to human exposure [12] . The final risk assessment thioridazine). Yet even when there is complete inhibition of prior to Phase I clinical trials has to be based on both the I current within the myocardium, episodes of TdP do not in vitro and in vivo data, with the latter derived from both Kr occur continuously: such electrophysiological conditions safety pharmacology and toxicology studies. Recommerely increase the risk of such episodes occurring. So mendations on optimal study design (both in vitro and in inhibition of I currents leads to two distinct, crucial vivo) have been offered previously [16] , several commenKr abnormalities, both reflected by QT prolongation: delayed tators have proposed strategies for preclinical [7, 48, 63 -65] repolarisation and instability of action potentials in Purand clinical assessment [7, 48, 66] of torsadogenic risk, and kinje fibres and M-cells, leading to the focal genesis of the current views of regulatory authorities have also been EADs, and dramatic transmural heterogeneity of ventricudiscussed, at least informally [67] [68] [69] . The capability of lar repolarisation, enabling propagation of the premature the pharmaceutical industry to detect QT prolongation in depolarising wavefront and the development of TdP preclinical tests has improved substantially over recent [8, 21, 55, 56, 66] . Drugs that merely prolong action potential years, but a significant challenge still remains to identify without causing instability, or do not result in QT disperproarrhythmic potential reliably. sion, would not necessarily be torsadogenic.
The following recommendations merely relate to the information that should be acquired before a decision is taken to enter clinical evaluation; exactly when these tests
. Summary and recommendations
are done is a matter of choice for the individual companies, and perhaps for individual projects within those com-5 .1. Importance of I inhibition as a feature of panies. So, our proposal would simply be as follows:
Kr torsadogenic agents (i) determine an IC at hERG in a transfected mam- 50 Our dataset has confirmed that I inhibition is a malian cell line;
Kr common feature of drugs that induce TdP in man (with the (ii) test the effects of the compound on mammalian exception of drugs that may induce or exacerbate myocarcardiac action potential in any well-characterised in dial ischaemia, resulting in TdP as an extremely rare vitro preparation; event). The available evidence indicates that block of (iii) test the compound for effects on QT interval in vivo, 1 hERG K channels (either selectively or in conjunction either by telemetry or using anaesthesia, applying with effects on other ion channels) is associated with TdP either a suitable correction for heart rate changes or a if it occurs at concentrations close to those achieved in regression approach [16] , or alternatively, cardiac 1 clinical use. Block of hERG K channels is a risk factor in pacing. drug-induced TdP, and probably the predominant risk factor, but it requires a combination of factors, possibly Much debate has taken place since the CPMP document coming together in a rare combination at one point in time [12] concerning the selection of an in vitro preparation for (i.e. over a few cardiac cycles), to trigger the event.
detecting drug-induced changes in cardiac action potential, and species differences have been studied systematically in 5 .2. Preclinical strategies for assessing torsadogenic risk the case of Purkinje fibres [70] . However, we feel that if accompanied by evaluation of hERG activity, the choice of Whilst our understanding of the relationship between preparation is less important than when this was the inhibition of I and the risk of TdP is progressing rapidly, mainstay of the in vitro evaluation. The reason for this is Kr that if a drug slows repolarisation in a concentrationof future drug development, candidate drugs with a margin dependent manner as predicted from its activity at hERG, smaller than 30-fold (for hERG IC , 10% increase in 50 then it can reasonably be assumed that it does not possess APD , or 10% increase in QT interval-whichever is the 90 significant activity at other cardiac ion channels (e.g. smallest margin) over the C , would probably require max cisapride). If it does not (e.g. terfenadine), then a further evaluation in a proarrhythmic model, and the clinical investigation of effects at other cardiac ion channels is programme may have to be augmented [12] . At the other required. Computer models may assist with interpretation end of the margin scale, despite our best efforts, some new of effects on action potential characteristics [71] . So, in drugs may induce TdP in susceptible individuals as brief, any well-characterised in vitro cardiac preparation extremely rare events by indirect mechanisms unrelated to may be used, according to the availability of tissue and the actions at ion channels. expertise within the laboratory, so long as the outcome is interpreted alongside the hERG data.
5 .4. 'Class effects'
.3. Safety margins
It is clear from our dataset that potency in hERG assays, prolongation of APD and QT, and torsadogenic risk, 90 1
Our dataset suggests that a margin of 30-fold between have little to do with therapeutic class. The hERG K hERG IC and C would be adequate to ensure an channel shows promiscuous binding characteristics across 50 max acceptable degree of safety from arrhythmogenesis, with a a wide range of chemical structures [53] . Obviously, if low risk of obtaining false positives. The same margin has similar molecular structures have been synthesized using been proposed previously based on opinion [65] , and has an opportunistic approach in order to improve on a also been suggested on the basis of a smaller dataset of marketed drug, then if one of these drugs has hERG drugs [72] . We would recommend that this margin is activity, this may well be shared by all its competitors to a acceptable for all drugs currently undergoing clinical greater or lesser extent, but this is not a 'class effect' in the development. However, for the future, one should aim for strictest sense of the term. Except in the case of Class Ia higher margins where possible, as then the concerns over and III antiarrhythmics, for adverse effects so remote from drug interactions, variable pharmacokinetics, and all the their target organs, and with a molecular mechanism quite other risk factors would recede. This would also address distinct from their primary molecular target, the use of the issues of inter-laboratory variability in hERG IC data: we term 'class effect' is unhelpful here. It is probably also 50 have used the lowest published hERG IC values to arrive unnecessary to invoke this term when considering tor- 50 at provisional safety margins, but it is likely that any single sadogenic risk, so long as preclinical data from the strategy laboratory would derive a value for any particular drug outlined above (hERG IC , effects on cardiac action 50 somewhere within the published range rather than at the potential, QT interval) are collated for submission to lower limit. regulatory authorities. Astemizole and cetirizine are both Obviously margins should reflect disease severity and non-sedating antihistamines, yet whereas astemizole is an medical need. For example, one could envisage that a extremely potent hERG blocker with a margin around 10-fold margin might be acceptable for drugs used in threefold, and was withdrawn after approximately 16 years diseases which are lethal if untreated (e.g. cancer, AIDS, on the market due to an unacceptable risk of TdP, cetirizine some other infections, etc.), a 30-fold margin may be is a very weak hERG blocker, with a margin approaching acceptable for drug treatments for serious debilitating 2000-fold, and has been used clinically for the same period diseases (e.g. stroke, Parkinson's disease, schizophrenia, of time without a single report of TdP. epilepsy, asthma, arthritis, etc.), but a margin of 100-fold or even higher might be required in the case of less serious 5 .5. Concluding remarks diseases (e.g. Raynaud's, seasonal rhinitis, eczema, etc.). These higher margins would also be appropriate for drugs Although 'torsade de pointes' was first characterized by prescribed to psychiatric patients at risk from suicidal Dessertenne in 1966 [73], the electrocardiographic features overdose. Furthermore, one has to consider changes to had been reported more than 40 years earlier [74] , and therapeutic target, patient population, and route of adminissudden deaths due to antipsychotic drugs were documented tration.
soon after their introduction in the 1950s [75] . It is The emphasis here should be on 'provisional margins as therefore not a new phenomenon, and the CPMP's 1997 a starting point' -an integrated evaluation of in vitro and 'Points to Consider' document [12] was arguably long in vivo electrophysiology data is essential for risk assessoverdue. Hopefully our survey of the published literature ment, and will ultimately be superseded by clinical data.
has helped to clarify the task of preclinical risk assessment Drugs with small margins for hERG activity are not with respect to proarrhythmic potential of new drugs. The necessarily unsafe, as evidenced by several that have been more drugs with a long track record of clinical use for in safe use for years, generally due to the mitigating effects which there are full datasets on in vitro and in vivo cardiac of actions at other ion channels. However, for the purposes electrophysiology, the clearer our understanding will be- 
